Shopping Cart
Remove All
Your shopping cart is currently empty
Enavatuzumab (Synonyms: PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361)
Catalog No. T76865 Copy Product Info
🥰Excellent
Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research.
Enavatuzumab
Copy Product Info🥰Excellent
Catalog No. T76865
Synonyms PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361
Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research.
Enavatuzumab
Cas No. 1062149-33-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $622 | In Stock | In Stock | |
| 10 mg | $993 | - | In Stock | |
| 25 mg | $1,470 | - | In Stock | |
| 50 mg | $1,980 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:98.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Enavatuzumab (PDL192) is a humanized monoclonal antibody targeting the TWEAK receptor (TWEAKR), with anti-tumor activity. It induces tumor growth inhibition by recruiting and activating myeloid effectors to kill tumor cells. It is used in late-stage solid tumor research. |
| In vitro | Enavatuzumab has growth inhibiting activity in a wide range of cancer cell lines in vitro. Enavatuzumab (10 μg/mL) and cells incubated together for 24 hours resulted in significantly increased migration of immune effector cells to SN12C and A375 tumor cells. [1] |
| In vivo | Enavatuzumab achieved 70% tumor growth inhibition (TGI) in vivo against H358 tumors.[2] |
| Synonyms | PDL-192, PDL192, Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody, ABT-361, ABT361 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | TNFRSF12A/TWEAKR/CD266 |
| Molecular Weight | 150 kDa |
| Cas No. | 1062149-33-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Enavatuzumab | purchase Enavatuzumab | Enavatuzumab cost | order Enavatuzumab | Enavatuzumab in vivo | Enavatuzumab in vitro | Enavatuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.